The oral anti-fibrotic treatment Ofev (nintedanib) was found to be generally well-tolerated among children and adolescents with fibrosing interstitial lung diseases (ILDs) in the Phase 3 InPedILD clinical trial. “Data from the InPedILD trial demonstrate that [Ofev] has an acceptable safety and tolerability profile in children and adolescents with…
Ofev Shows Good Safety Profile in Children With Fibrosing ILDs
Patients receiving a higher dose of PLN-74809 in the Phase 2a INTEGRIS-IPF clinical trial, which is testing the oral treatment candidate for idiopathic pulmonary fibrosis (IPF), are showing positive safety outcomes. That’s according to data from a safety review analysis conducted by the study’s data safety monitoring board (DSMB)…
I’ve been writing this column for almost six years. Throughout that time, I’ve had the privilege of interacting with other patients living with idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease. While IPF is considered a rare disease, it doesn’t always feel that way given how many…
NP-120 (ifenprodil), an investigational treatment for idiopathic pulmonary fibrosis (IPF) and chronic cough, continues to demonstrate an ability to preserve lung function and ease cough, according to analyses of secondary goals in a Phase 2a trial. Most of these analyses related to patient-reported outcomes, supplementing positive top-line data from…
One of the more difficult parts of my journey has been remembering those I’ve met or learned of who’ve passed away from pulmonary fibrosis (PF). There are so many. It’s why we must all move forward in pursuit of treatments and a cure. The pulmonary fibrosis community must…
Focusing on raising awareness of interstitial lung diseases (ILDs), nine organizations, including the Pulmonary Fibrosis Foundation (PFF), are working together to present the second annual ILD Day, taking place Sept. 14. More than 50,000 Americans are diagnosed every year with ILD, a group of lung diseases marked by inflammation…
AstraZeneca’s experimental oral therapy saracatinib — originally developed to treat certain cancers — was found to be at least as effective, and even superior to the approved therapies Ofev (nintedanib) and Esbriet (pirfenidone) in treating idiopathic pulmonary fibrosis (IPF) in several preclinical models of the respiratory disease. Saracatinib worked…
During my pulmonary fibrosis journey, I learned that one of the best things I could do for myself was to become an active voice on my care team. As a patient diagnosed with idiopathic pulmonary fibrosis (IPF) more than five years ago, I wanted to know more about this…
From sharing stories and “going blue,” to offering yoga sessions and hosting community walks, patients and supporters are set to mark Pulmonary Fibrosis Awareness Month, held annually in September. The effort is also aimed at raising research funds to fight pulmonary fibrosis (PF), which is part of a group…
By definition, a progressive illness is one that worsens over time. When I was diagnosed in 2016 with idiopathic pulmonary fibrosis (IPF), a life-threatening and progressive lung disease, I was told by a pulmonologist that simple tasks would become difficult as the fibrosis in my lungs worsened. Before IPF,…
